Mahamaya Lifesciences IPO GMP: Day 1 IPO Live Updates

Click & Sign Up to Get Latest Updates on Mahamaya Lifesciences

The Mahamaya Lifesciences IPO GMP is ₹0 as of 11th November 2025. It is a book-building IPO of ₹70.44 crore, comprising a fresh issue of 56,00,000 shares. The issue will be listed on BSE and SME on its tentative listing date, 18th November 2025. The face value of Mahamaya Lifesciences shares is ₹10 per share, and the IPO price band is set at ₹108 to ₹114 per share. Retail investors can bid for a minimum of 2 lots of 2,400 shares, worth ₹2,73,600.

Mahamaya Lifesciences IPO Grey Market Premium

As of 11th November 2025, the GMP for the Mahamaya Lifesciences stands at ₹0 per share. Thus, the estimated listing price would be ₹114. This indicates that the estimated listing gain in this IPO could be 0.00%. However, GMP details are subject to change based on market conditions and fluctuations. Explore the table for GMP updates on the Mahamaya Lifesciences.

Mahamaya Lifesciences Details

Explanation

Mahamaya Lifesciences: Mahamaya Lifesciences Limited has announced the issue price of ₹108 to ₹114 per share. With this IPO, the company allows retail investors to bid for two lots of 2,400 shares worth ₹2,73,600. The face value of Mahamaya Lifesciences Limited shares is ₹10 per share. The shares of Mahamaya Lifesciences Limited will be listed on BSE and SME on its tentative listing day, 18th November 2025. Scroll down to view GMP updates and reviews of the Mahamaya Lifesciences. 

Objectives of the Mahamaya Lifesciences

The primary objective of the Mahamaya Lifesciences IPO is to raise ₹70.44 crore. However, before applying for the IPO, it is essential to be aware of its secondary objectives. Explore them below

• Purchase of Equipment for the existing Formulation plant
• Funding capital expenditure towards setting up a new technical manufacturing plant
• Construction of Warehouse Building and Purchase of Machinery
• Funding the working capital requirement of our Company
• General Corporate purposes

Mahamaya Lifesciences Registrar

According to recent updates, Kfin Technologies Private Limited will be the registrar responsible for managing allotment and refund procedures. For any queries regarding the Mahamaya Lifesciences IPO GMP, allotment, and refund, you can contact Kfin Technologies Limited at  reachus@kfintech.com  or 04067162222, 04079611000.

Mahamaya Lifesciences IPO Review  

The Mahamaya Lifesciences has gained neutral ratings from industry experts, brokers, and institutional investors. Mahamaya Lifesciences Limited’s revenue increased by 64% from ₹162.83 crore in March 2024 to ₹267.17 crore in March 2025. Moreover, the company’s PAT increased by 148% from ₹5.22 crores to ₹12.94 crores. Investors can analyse pertinent other factors and make a decision accordingly.

Most analysts recommend applying for this IPO to diversify your investment portfolio. However, we’re waiting for further ratings to gain a better understanding and will continue to post them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Mahamaya Lifesciences or not.

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Mahamaya Lifesciences.

The P/E ratio of Mahamaya Lifesciences Limited’s shares is 15.65, and its Earnings Per Share (EPS) is 7.29. Thus, the Mahamaya Lifesciences Limited IPO can deliver gains on its tentative listing day, 18th November 2025

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Mittal Solutions Limited are subject to change following the IPO. Refer to the table below for post-issue updates on these two metrics. 

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

FAQs on Mahamaya Lifesciences

What is the GMP of the Mahamaya Lifesciences?

Ans. As of 11th November 2025, the Mahamaya Lifesciences (Grey Market Premium) stands at ₹0. This suggests that the estimated listing price could be 0.00% of the share price.

What is the issue price of the Mahamaya Lifesciences?

Ans. The Mahamaya Lifesciences IPO price range is ₹108.00 to ₹114.00 per share. Retail investors can apply for a minimum of 2 lots, each consisting of 2,400 shares, worth ₹2,73,600. Moreover, HNIs are required to bid for a minimum of 3 lots (3,600 shares) worth ₹4,10,400.

Who is the registrar of the Mahamaya Lifesciences?

According to recent updates, Kfin Technologies Private Limited will be the registrar responsible for managing allotment and refund procedures. For any queries regarding the Mahamaya Lifesciences IPO GMP, allotment, and refund, you can contact Kfin Technologies Limited at  reachus@kfintech.com or 04067162222, 04079611000.

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Mahamaya Lifesciences, download the Mahamaya Lifesciences RHP and Mahamaya Lifesciences DRHP. Conduct thorough research before investing in IPOs to minimise the risk of significant losses. You can also consult your financial advisor.

Recent Articles

Top 10 Penny Stocks in India  | Penny Stocks to Buy in 2025

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Accelerator IPO GMP & Review: Apply or Avoid?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates